U.S. National Institutes of Health  |  www.cancer.gov

NATIONAL
CANCER
INSTITUTE
NCI Cancer Bulletin
A Trusted Source for Cancer Research News
Special Issue
November 20, 2007 • Volume 4 / Number 30 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe


Bulletin Home

Director's Update
NCI-Frederick's Unique Combination of Resources and Flexibility

NCI-Frederick to Help Build Proteomics Pipeline

Highlights in the History of NCI-Frederick

A Conversation with
Dr. Craig Reynolds

A National Treasury of Biological Specimens

Drug Discovery and Development at NCI-Frederick

From the Ends of the Earth, the Search for a Cure

A Unique Animal Imaging Program

A Closer Look at Nanotechnology

A Good Neighbor to Nearby Communities

How to Subscribe

Legislative Update

Cancer Research Highlights
Cetuximab Provides Slight Survival Advantage in Advanced Colorectal Cancer

Tool Uses Three Factors to Assess Breast Cancer Risk

Decline in Adult Smoking Stalls, Rates Still High in Some Subgroups

Analysis Indicates Letrozole, Tamoxifen Safe in Early Breast Cancer

Family Program Helps Prostate Cancer Patients and Spouses Cope

Bulletin Archive

About the Bulletin
Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
SSpecial Issue Page Banner: Banner shows a double-helix DNA strand with photos of researchers, marine creatures, imaging equipment, laboratory equipment, and plant leaves in the foreground.
Highlights in the History of NCI-Frederick
2007 2005 Clinical Proteomic Technologies Initiative begins 2006 Vaccine Pilot Plant opens 2005 Nanotechnology Characterization Laboratory opens 1998 Rapid Access to Intervention Development begins to speed up the transfer of investigational drugs into clinical trials 1990 The first NCI letter of collection is signed with the Republic of Madagascar, 3 years before the Convention on Biodiversity 1986 The Natural Products Repository is established. The first supercomputer dedicated to biomedical research is established at NCI-Frederick Image of an NCI-Frederick researcher holding a pipette next to a computer. 1998 Rapid Access to Intervention Development begins to speed up the transfer of investigational drugs into clinical trials 1993 Biopharmaceutical Development Program begins to support prototype drugs, vaccines, and other therapies. Large-scale production of geldanamycin (more than 3 kilograms) begins in the NCI-Frederick fermentation plant's 10,000L fermentor, which permits the introduction of 17-allylaminogeldanamycin (17-AAG) as the first signal-transduction molecule in human clinical trials. Taxol is approved for use by the FDA. 1992 Two anti-HIV plant-derived agents are identified by NCI scientists from collections in Cameroon (Michellamine B) and in Sarawak (Calanolide A); large-scale collection and horticultural programs established in these countries 1991 The Natural Products Repository begins distribution to permit intra- and extramural investigators of all types to study samples collected and processed at NCI-Frederick 1992 Two anti-HIV plant-derived agents are identified by NCI scientists from collections in Cameroon (Michellamine B) and in Sarawak (Calanolide A); large-scale collection and horticultural programs established in these countries 1991 The Natural Products Repository begins distribution to permit intra- and extramural investigators of all types to study samples collected and processed at NCI-Frederick 1981 Biological Response Modifiers Program is established to bring new therapeutic agents to clinical trials 1977 Taxol is developed from samples of the Pacific yew tree's bark, which came from the Natural Products Branch's previous collection program with the USDA 1975 NCI-Frederick is designated as an FFRDC dedicated to biomedical research 1972 NCI-Frederick is established at Fort Detrick in Frederick, Maryland 1972 Image of a researcher at NCI-Frederick in a protective suit. 1990 The first NCI letter of collection is signed with the Republic of Madagascar, 3 years before the Convention on Biodiversity 1985 HIV antibody testing begins at NCI-Frederick, leading to a test used to safeguard the nation's blood supply against contamination 1982 Central Repository is established to assist investigators in storing research specimens 1981 Biological Response Modifiers Program is established to bring new therapeutic agents to clinical trials Image of the supercomputer at NCI-Frederick. Image of the Central Repository at NCI-Frederick.

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov